The American Society of Tropical Medicine and Hygiene has waived the Open Access fee for this article due to the ongoing COVID-19 pandemic and has assisted with publication expenses.
Zhu Z, Lian X, Su X, Wu W, Marraro GA, Zeng Y , 2020. From SARS and MERS to COVID-19: a brief summary and comparison of severe acute respiratory infections caused by three highly pathogenic human coronaviruses. Respir Res 21: 1–14.
Abdelghany T, Ganash M, Bakri MM, Qanash H, Al-Rajhi AM, Elhussieny NI , 2021. SARS-CoV-2, the other face to SARS-CoV and MERS-CoV: future predictions. Biomed J 44: 86–93.
Chu H, Chan JF-W, Wang Y, Yuen TT-T, Chai Y, Shuai H, Yang D, Hu B, Huang X, Zhang X , 2021. SARS-CoV-2 induces a more robust innate immune response and replicates less efficiently than SARS-CoV in the human intestines: an ex vivo study with implications on pathogenesis of COVID-19. Cell Mol Gastroenterol Hepatol 11: 771–781.
- Search Google Scholar
- Export Citation
Chu H Chan JF-W Wang Y Yuen TT-T Chai Y Shuai H Yang D Hu B Huang X , Zhang X 2021. SARS-CoV-2 induces a more robust innate immune response and replicates less efficiently than SARS-CoV in the human intestines: an ex vivo study with implications on pathogenesis of COVID-19. Cell Mol Gastroenterol Hepatol 11: 771– 781.
Kukla M, Skonieczna-Żydecka K, Kotfis K, Maciejewska D, Łoniewski I, Lara L, Pazgan-Simon M, Stachowska E, Kaczmarczyk M, Koulaouzidis A , 2020. COVID-19, MERS and SARS with concomitant liver injury—systematic review of the existing literature. J Clin Med 9: 1420.
Itou M, Kawaguchi T, Taniguchi E, Sata M , 2013. Dipeptidyl peptidase-4: a key player in chronic liver disease. World J Gastroenterol 19: 2298.
Wu K-L, Lu S-N, Changchien C-S, Chiu K-W, Kuo C-H, Chuah S-K, Liu J-W, Lin M-C, Eng H-L, Chen S-S , 2004. Sequential changes of serum aminotransferase levels in patients with severe acute respiratory syndrome. Am J Trop Med Hyg 71: 125–128.
Saad M, Omrani AS, Baig K, Bahloul A, Elzein F, Matin MA, Selim MA, Al Mutairi M, Al Nakhli D, Al Aidaroos AY , 2014. Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia. Int J Infect Dis 29: 301–306.
- Search Google Scholar
- Export Citation
Saad M Omrani AS Baig K Bahloul A Elzein F Matin MA Selim MA Al Mutairi M Al Nakhli D , Al Aidaroos AY 2014. Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia. Int J Infect Dis 29: 301– 306.
Al-Hameed F, Wahla AS, Siddiqui S, Ghabashi A, Al-Shomrani M, Al-Thaqafi A, Tashkandi Y , 2016. Characteristics and outcomes of Middle East respiratory syndrome coronavirus patients admitted to an intensive care unit in Jeddah, Saudi Arabia. J Intensive Care Med 31: 344–348.
Kumar-M P, Mishra S, Jha DK, Shukla J, Choudhury A, Mohindra R, Mandavdhare HS, Dutta U, Sharma V , 2020. Coronavirus disease (COVID-19) and the liver: a comprehensive systematic review and meta-analysis. Hepatol Int 14: 711–722.
Hong K-H, Choi J-P, Hong S-H, Lee J, Kwon J-S, Kim S-M, Park SY, Rhee J-Y, Kim B-N, Choi HJ , 2018. Predictors of mortality in Middle East respiratory syndrome (MERS). Thorax 73: 286–289.
Chau TN, Lee KC, Yao H, Tsang TY, Chow TC, Yeung YC, Choi KW, Tso YK, Lau T, Lai ST , 2004. SARS‐associated viral hepatitis caused by a novel coronavirus: report of three cases. Hepatology 39: 302–310.
Portincasa P, Krawczyk M, Machill A, Lammert F, Di Ciaula A , 2020. Hepatic consequences of COVID-19 infection. Lapping or biting? Eur J Intern Med 77: 18–24.
Ding Y, He L, Zhang Q, Huang Z, Che X, Hou J, Wang H, Shen H, Qiu L, Li Z, 2004. Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS‐CoV) in SARS patients: implications for pathogenesis and virus transmission pathways. J Pathol 203: 622–630.
Ng DL, Al Hosani F, Keating MK, Gerber SI, Jones TL, Metcalfe MG, Tong S, Tao Y, Alami NN, Haynes LM , 2016. Clinicopathologic, immunohistochemical, and ultrastructural findings of a fatal case of Middle East respiratory syndrome coronavirus infection in the United Arab Emirates, April 2014. Am J Pathol 186: 652–658.
- Search Google Scholar
- Export Citation
Ng DL Al Hosani F Keating MK Gerber SI Jones TL Metcalfe MG Tong S Tao Y Alami NN , Haynes LM 2016. Clinicopathologic, immunohistochemical, and ultrastructural findings of a fatal case of Middle East respiratory syndrome coronavirus infection in the United Arab Emirates, April 2014. Am J Pathol 186: 652– 658.
Marjot T, Moon AM, Cook JA, Abd-Elsalam S, Aloman C, Armstrong MJ, Pose E, Brenner EJ, Cargill T, Catana M-A , 2021. Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: an international registry study. J Hepatol 74: 567–577.
Iavarone M, D’Ambrosio R, Soria A, Triolo M, Pugliese N, Del Poggio P, Perricone G, Massironi S, Spinetti A, Buscarini E , 2020. High rates of 30-day mortality in patients with cirrhosis and COVID-19. J Hepatol 73: 1063–1071.
Rahman A, Niloofa R, Jayarajah U, De Mel S, Abeysuriya V, Seneviratne SL , 2021. Hematological abnormalities in COVID-19: a narrative review. Am J Trop Med Hyg 104: 1188.
Nardo AD, Schneeweiss‐Gleixner M, Bakail M, Dixon ED, Lax SF, Trauner M , 2021. Pathophysiological mechanisms of liver injury in COVID‐19. Liver Int 41: 20–32.
Wu J, Song S, Cao HC, Li LJ , 2020. Liver diseases in COVID-19: etiology, treatment and prognosis. World J Gastroenterol 26: 2286–2293.
Ji D, Qin E, Xu J, Zhang D, Cheng G, Wang Y, Lau G , 2020. Non-alcoholic fatty liver diseases in patients with COVID-19: a retrospective study. J Hepatol 73: 451–453.
Rahman A, Niloofa R, De Zoysa IM, Cooray AD, Kariyawasam J, Seneviratne SL , 2020. Neurological manifestations in COVID-19: a narrative review. SAGE Open Med 8: 2050312120957925.
Bertolini A et al.2020. Abnormal liver function tests in patients with COVID-19: relevance and potential pathogenesis. Hepatology 72: 1864–1872.
Barlow A, Landolf KM, Barlow B, Yeung SYA, Heavner JJ, Claassen CW, Heavner MS , 2020. Review of emerging pharmacotherapy for the treatment of coronavirus disease 2019. Pharmacotherapy. J Hum Pharmacol Drug Ther 40: 416–437.
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G , 2020. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30: 269–271.
Deng L, Li C, Zeng Q, Liu X, Li X, Zhang H, Hong Z, Xia J , 2020. Arbidol combined with LPV/r versus LPV/r alone against corona virus disease 2019: a retrospective cohort study. J Infect 81: e1–e5.
ClinicalTrials.gov [Internet] , 2020. Lopinavir/Ritonavir, Ribavirin and IFN-Beta Combination for nCoV Treatment. Cg, Bethesda MNLoMUF-IN IN. February 28, 2020. [Cited July 29, 2020]; [about 4 screens].
ClinicalTrials.gov, [Internet] , 2012. Darunavir. LCaRIoD-ILI, Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases. [Updated September 1, 2017].
Joshi S, Parkar J, Ansari A, Vora A, Talwar D, Tiwaskar M, Patil S, Barkate H, 2020. Role of favipiravir in the treatment of COVID-19. Int J Infect Dis 102: 501–508.
Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, Stebbing J , 2020. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet 395: e30.
ClinicalTrials.gov [Internet] , 2020. Baricitinib Therapy in COVID-19. Cg, Bethesda MNLoMUM-IN IN. Identifire NCT04358614. July 22, 2020 [Cited July 29, 2020].
Emadi A, Chua JV, Talwani R, Bentzen SM, Baddley J , 2020. Safety and efficacy of imatinib for hospitalized adults with COVID-19: a structured summary of a study protocol for a randomised controlled trial. Trials 21: 1–5.
ClinicalTrials.gov [Internet] , 2012. Hydroxychloroquine. LCaRIoD-ILI, Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases. [Updated March 25, 2018].
ClinicalTrials.gov [Internet] , 2020. Efficacy of Dexamethasone Treatment for Patients with ARDS Caused by COVID-19 (DEXA-COVID19). Bethesda, MD: MNLoMUMIN IN. September 2, 2020 [Cited July 29, 2020].
Centre for Evidence-Based Medicine, Nuffield Department of Primary Care Health Sciences University of Oxford, 2020. Available at: https://www.phc.ox.ac.uk/research/oxford-centre-for-evidence-based-medicine. Accessed February 19, 2022.
ClinicalTrials.gov [Internet] , 2020. Azithromycin in Hospitalized COVID-19 Patients (AIC). Cg, Bethesda MNLoMUJIN0. Identifier: NCT04359316. [Cited December 6, 2020].
Anonymous , 2021. Conditions for use, conditions for distribution and patients targeted and conditions for safety monitoring addressed to member states for unauthorized product PAXLOVID (PF-07321332 150 mg and ritonavir 100 mg). Available at: https://www.ema.europa.eu/en/documents/referral/paxlovid-pf-07321332-ritonavir-covid-19-article-53-procedure-conditions-use-conditions-distribution_en.pdf. Accessed December 24, 2021.
Anonymous, 2021. Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study. Available at: https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/#:~:text=At%20the%20interim%20analysis%2C%20molnupiravir,%2F377)%3B%20p%3D0.0012. Accessed December 20, 2020.
Forbes JD, Van Domselaar G, Bernstein CN , 2016. The gut microbiota in immune-mediated inflammatory diseases. Front Microbiol 7: 1081.
Chattopadhyay I, Shankar EM , 2021. SARS-CoV-2-indigenous microbiota nexus: does gut microbiota contribute to inflammation and disease severity in COVID-19? Front Cell Infect Microbiol 11: 96.
Yeoh YK et al.2021. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut 70: 698–706.
Terruzzi I, Senesi P , 2020. Does intestinal dysbiosis contribute to an aberrant inflammatory response to SARS-CoV-2 in frail patients? Nutrition 79: 110996.
Yang Q, Liang Q, Balakrishnan B, Belobrajdic DP, Feng Q-J, Zhang W , 2020. Role of dietary nutrients in the modulation of gut microbiota: a narrative review. Nutrients 12: 381.
Rishi P, Thakur K, Vij S, Rishi L, Singh A, Kaur IP, Patel SK, Lee J-K, Kalia VC , 2020. Diet, gut microbiota and COVID-19. Indian J Microbiol 60: 420–429.
Koliaki C et al.2015. Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis. Cell Metab 21: 739–746.
Sun J, Aghemo A, Forner A, Valenti L, 2020. COVID-19 and liver disease. Liver Int 40: 1278--1281.
Yang R-X, Zheng R-D, Fan J-G , 2020. Etiology and management of liver injury in patients with COVID-19. World J Gastroenterol 26: 4753.
Kariyawasam JC, Jayarajah U, Riza R, Abeysuriya V, Seneviratne SL, 2021. Gastrointestinal manifestations in COVID-19. Trans R Soc Trop Med Hyg trab042.
Li Y, Xiao SY , 2020. Hepatic involvement in COVID-19 patients: pathology, pathogenesis, and clinical implications. J Med Virol 92: 1491–1494.
Lei F et al.2020. Longitudinal association between markers of liver injury and mortality in COVID-19 in China. Hepatology 72: 389–398.
Abe K et al.2020. Clinical features and liver injury in patients with COVID-19 in the Japanese population. Intern Med 59: 2353–2358.
Beigmohammadi MT, Jahanbin B, Safaei M, Amoozadeh L, Khoshavi M, Mehrtash V, Jafarzadeh B, Abdollahi A , 2021. Pathological findings of postmortem biopsies from lung, heart, and liver of 7 deceased COVID-19 patients. Int J Surg Pathol 29: 135–145.
Chen N et al.2020. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395: 507–513.
Effenberger M et al.2020. Liver stiffness by transient elastography accompanies illness severity in COVID-19. BMJ Open Gastroenterol 7: e000445.
Jin X et al.2020. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut 69: 1002–1009.
Luo S, Zhang X, Xu H , 2020. Don’t overlook digestive symptoms in patients with 2019 novel coronavirus disease (COVID-19). Clin Gastroenterol Hepatol 18: 1636–1637.
Mo P et al., 2020. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. Clin Infect Dis ciaa270.
Pan L et al.2020. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. Am J Gastroenterol 115: 766–773.
Singh S, Khan A , 2020. Clinical characteristics and outcomes of coronavirus disease 2019 among patients with preexisting liver disease in the United States: a multicenter research network study. Gastroenterology 159: 768–771.e3.
Xu XW et al.2020. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ 368: m606.
Xu Y et al.2020. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding. Nat Med 26: 502–505.
Wang Y et al.2020. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. J Hepatol 73: 807–816.
Zhou F et al.2020. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395: 1054–1062.
Xu Z et al.2020. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 8: 420–422.
Fan Z, Chen L, Li J, Cheng X, Yang J, Tian C, Zhang Y, Huang S, Liu Z, Cheng J , 2020. Clinical features of COVID-19-related liver functional abnormality. Clin Gastroenterol Hepatol 18: 1561–1566.
Xie H, Zhao J, Lian N, Lin S, Xie Q, Zhuo H , 2020. Clinical characteristics of non-ICU hospitalized patients with coronavirus disease 2019 and liver injury: a retrospective study. Liver Int 40: 1321–1326.
Paliogiannis P, Zinellu A , 2020. Bilirubin levels in patients with mild and severe COVID-19: a pooled analysis. Liver Int 40: 1787–1788.
Bernal-Monterde V et al.2020. SARS-CoV-2 infection induces a dual response in liver function tests: association with mortality during hospitalization. Biomedicines 8: 328.
Liu Z et al.2020. Bilirubin levels as potential indicators of disease severity in coronavirus disease patients: a retrospective cohort study. Front Med 7: 598870.